

# Donanemab-azbt (Kisunla) 1<sup>st</sup> Infusion Only

Provider Order Form rev. 10/28/25



## PATIENT INFORMATION

Referral Status:  New Referral  Updated Order  Order Renewal

Date:	Patient Name:	DOB:
ICD-10 code (required):	ICD-10 description:	
<input type="checkbox"/> NKDA Allergies:	Weight (lbs/kg):	Height:
<b>Patient Status:</b> <input type="checkbox"/> New to Therapy    Next Due Date:		

## PROVIDER INFORMATION

Referral Coordinator Name:	Referral Coordinator Email:		
Ordering Provider:	Provider NPI:		
Referring Practice Name:	Phone:	Fax:	
Practice Address:	City:	State:	Zip Code:

## REFERRING PROVIDER

- I have reviewed the prescribing information and medication guide for Kisunla (donanemab-azbt)
- I acknowledge IVX Health clinicians will provide nursing care per IVX Nursing Procedures, including reaction management and post-procedure observation **NOTE:** IVX Adverse Reaction Management Protocol available for review at [www.ivxhealth.com/forms](http://www.ivxhealth.com/forms) (version 05.01.2023)
- Provide supporting [clinical documentation](#) including:
  - Positive amyloid beta pathology testing (Amyloid Beta PET Scan or biomarker testing)
  - Clinical documentation including a neurologic evaluation supporting accurate diagnosis and eligibility of mild cognitive impairment or mild dementia. Ex: Mini Mental Status Exam (MMSE)
  - [ARIA MRI Classification Criteria](#): If  $\geq 5$  new incident microhemorrhages or  $> 2$  new focal areas of superficial siderosis (indicating moderate radiographic severity for ARIA-H) are observed, treatment will not be initiated until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. If any of the following are noted: FLAIR hyperintensity  $> 5$  cm in a single greatest dimension, more than 1 site of involvement, gyral swelling or sulcal effacement (indicating moderate radiographic severity for ARIA-E), treatment must be suspended until MRI demonstrates radiographic resolution and symptoms, if present, resolve
- I, the prescribing provider, am responsible for ordering and reviewing all MRIs of the brain for this patient. By checking this box, I acknowledge that I have obtained and reviewed a baseline (within 1 year) MRI and communicated the results to the patient or his/her legal guardian. IVX Health is safe to proceed with the patient's donanemab-azbt (Kisunla) infusion**

## PRE-MEDICATION ORDERS (OPTIONAL AND NOT REQUIRED BY MANUFACTURER)

- acetaminophen (Tylenol)  500mg /  650mg /  1000mg PO
- cetirizine (Zyrtec) 10mg PO
- loratadine (Claritin) 10mg PO
- diphenhydramine (Benadryl)  25mg /  50mg  PO /  IV
- methylprednisolone (Solu-Medrol)  40mg /  125mg IV
- Other: \_\_\_\_\_
- Dose: \_\_\_\_\_ Route: \_\_\_\_\_
- Frequency: \_\_\_\_\_

## REQUIRED DOCUMENTATION

Referring providers must register patients with Medicare and Medicare Advantage in the CMS registry and provide proof of registration prior: <https://qualitynet.cms.gov/alzheimers-ced-registry/submission>

### Attach proof of CMS Registry Confirmation or provide below:

Issue Number: ALZH-\_\_\_\_\_

Date of Submission: \_\_\_\_\_

## THERAPY ADMINISTRATION

Kisunla (donanemab-azbt) will be prepared and infused according to the [prescribing information](#) provided by the manufacturer. **NOTE: IVX Health will pursue an authorization per the dosing schedule outlined in the manufacturer's PI. However, a new order and subsequent MRIs of the brain must be completed and reviewed prior to the 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>, and 7<sup>th</sup> Kisunla (donanemab-azbt) infusions**

- **Preparation:** Prepare Kisunla (donanemab-azbt) to achieve a final concentration of 4 mg/mL to 10 mg/mL per manufacturer guidelines.
- **Dose:** Kisunla (donanemab-azbt) 350 mg IV
- **Rate:** Infuse over 30 minutes
- **Frequency:** Every four weeks for 1 dose.
- **Post Infusion:** Flush with 0.9% Sodium Chloride at the completion of infusion. Monitor patient for 30 minutes post infusion

Provider Name (Print)	Provider Signature	Date
<b>IVX HEALTH FAX NUMBERS</b>	<input type="checkbox"/> CHICAGO: 312-253-7244 <input type="checkbox"/> EAST TN/TRI-CITIES: 615-425-7427 <input type="checkbox"/> MELBOURNE: 321-800-9515 <input type="checkbox"/> PIEDMONT TRIAD: 336-790-2200 <input type="checkbox"/> CINCINNATI: 844-946-0868 <input type="checkbox"/> FT. LAUDERDALE: 754-946-2052 <input type="checkbox"/> MIAMI: 786-744-5687 <input type="checkbox"/> RALEIGH: 919-287-2551 <input type="checkbox"/> COLLEGE STN: 979-205-4686 <input type="checkbox"/> HARRISBURG: 844-859-4235 <input type="checkbox"/> MIDDLE/WEST TN: 888-615-1445 <input type="checkbox"/> SAN ANTONIO: 726-238-9950 <input type="checkbox"/> COLUMBUS: 844-627-2675 <input type="checkbox"/> HOUSTON: 832-631-9595 <input type="checkbox"/> NORTH CENTRAL FL: 352-756-4191 <input type="checkbox"/> SARASOTA: 941-870-6550 <input type="checkbox"/> ARKANSAS: 501-451-5644 <input type="checkbox"/> CONNECTICUT: 860-955-1532 <input type="checkbox"/> INDIANAPOLIS: 844-983-2028 <input type="checkbox"/> NORTH JERSEY: 551-227-2823 <input type="checkbox"/> SOUTH JERSEY: 856-519-5309 <input type="checkbox"/> AUSTIN: 512-772-2824 <input type="checkbox"/> DALLAS: 469-947-6114 <input type="checkbox"/> JACKSONVILLE: 904-212-2338 <input type="checkbox"/> ORLANDO: 844-946-0867 <input type="checkbox"/> SOUTHWEST FL: 813-283-9144 <input type="checkbox"/> BAY AREA: 844-889-0275 <input type="checkbox"/> DAYTONA: 386-259-6096 <input type="checkbox"/> KANSAS CITY: 844-900-1292 <input type="checkbox"/> PALM BEACH: 561-768-9044 <input type="checkbox"/> TAMPA: 844-946-0849 <input type="checkbox"/> CHARLOTTE: 336-663-0143 <input type="checkbox"/> DELAWARE: 302-596-8553 <input type="checkbox"/> LAKELAND: 863-316-3910 <input type="checkbox"/> PHILADELPHIA: 844-820-9641 <input type="checkbox"/> WACO: 254-343-7650	